Clinical Trial

A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the real world efficacy and safety of the liposomal irinotecan (Onivyde®)-based treatment scheme in Chinese patients with locally advanced or metastatic pancreatic cancer, and to compare the efficacy with that of the whole pancreatic cancer population who did not receive relevant treatment.
Trial Details
NCT Number NCT07026123
Lead Sponsor RenJi Hospital
Collaborators: Servier (Tianjin) Pharmaceutical Co. LTD.
Conditions Advanced Pancreatic Cancer
Enrollment 40 participants
Start Date 2025-07-01
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-18